TakadaMEngelkeKHagiwaraS. Assessment of osteoporosis: comparison of radiographic absorptiometry of the phalanges and dual x-ray absorptiometry of the radius and the lumbar spine. Radiology, 1997; 202: 759–63.
2.
PatersonCRDual energy x-ray absorptiometry may not be the gold standard. Br Med J, 1996: 312: 1225.
3.
SchwartzHA. Measurement of bone density: comment on the American College of Rheumatology recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum1997: 40: 1551.
4.
WasnichRD. Consensus and the T-score fallacy. Clin Rheumatol, 1997; 16: 337–39.
5.
NguyenTVKellyPJSambrookPN. Lifestyle factors and bone density in the elderly: implications for osteoporosis prevention. J Bone Miner Res, 1994; 9: 1339–46.
6.
LawMRHackshawAKA meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. Br Med J1997; 315: 841–46.
7.
KielDPBaronJAAndersonJJ. Smoking eliminates the protective effect of oral estrogens on the risk of hip fracture among women. Ann Intern Med, 1992; 116: 716–21.
8.
Dawson-HughesBHarrisSSKrallEADallalGE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. New Engl J Med, 1997; 337: 670–76.
9.
BlackDMCummingsSRKarpfDB. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet, 1996; 348: 1535–41.
10.
de GroenPCLubbeDFHirschLJ. Esophagitis associated with the use of alendronate. New Engl J Med, 1996; 335: 1016–21.
11.
LevineJNelsonD. Esophageal stricture associated with alendronate therapy. Am J Med, 1997; 102: 489–91.
12.
AdachiJDBensenWGBrownJ. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. New Engl J Med, 1997; 337: 382–87.
